Arrowhead Pharmaceuticals (ARWR) – Research Analysts’ Recent Ratings Updates
A number of firms have modified their ratings and price targets on shares of Arrowhead Pharmaceuticals (NASDAQ: ARWR) recently:
- 12/12/2017 – Arrowhead Pharmaceuticals was given a new $2.00 price target on by analysts at Cantor Fitzgerald. They now have a “hold” rating on the stock.
- 12/2/2017 – Arrowhead Pharmaceuticals was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
- 11/30/2017 – Arrowhead Pharmaceuticals was upgraded by analysts at ValuEngine from a “strong sell” rating to a “sell” rating.
- 11/27/2017 – Arrowhead Pharmaceuticals was upgraded by analysts at Piper Jaffray Companies from a “neutral” rating to an “overweight” rating. They now have a $5.50 price target on the stock.
Shares of Arrowhead Pharmaceuticals Inc (NASDAQ ARWR) traded down $0.15 on Thursday, hitting $3.40. 2,037,300 shares of the stock were exchanged, compared to its average volume of 981,378. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.84 and a current ratio of 3.84. Arrowhead Pharmaceuticals Inc has a twelve month low of $1.20 and a twelve month high of $4.54.
Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.
Receive News & Ratings for Arrowhead Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.